1) Albinama_Table1.dta: Baseline characteristics of cohort; 2) Albinama_Table2_Po: Survival analyses of risk of P. ovale infections; 3) Albinama_Table2_Pv_clin: Survival analyses of incidence risk of P. vivax clinical episodes; 4) Albinama_Table2_Pv_LM: survival analyses of incidence risk of light-microscopically positive P. vivax infections; 5) Albinama_Table2_Pv_PCR: survival analyses of incidence risk of PCR positive P. vivax infections; 6)Albinama_Table2_Pvg: survival analyses of incidence risk of gametocyte positive P. vivax infections; 7) Albinama_Table3_0-3mo: incidence of malaria endpoints for first 3 months of follow-up; 8) Albinama_Table3_4-8mo: incidence of malaria endpoints for months 4-8 of follow-up; 9) Albinama_Table3_0-8mo: incidence of malaria endpoints for entire 8 months follow-up; 10) Albinama_Table4_Pf_clin: Survival analyses of incidence risk of P. falciparum clinical episodes; 11) Albinama_Table4_Pf_LM: survival analyses of incidence risk of light-microscopically positive P. falciparum infections; 12) Albinama_Table4_Pf_PCR: survival analyses of incidence risk of PCR positive P. falciparum infections; 13)Albinama_Table4_Pm_PCR: survival analyses of incidence risk of PCR positive P. malariae infections
